| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 41 | 2025 | 382 | 9.920 |
Why?
|
| Carcinoma, Transitional Cell | 22 | 2025 | 156 | 5.410 |
Why?
|
| Kidney Neoplasms | 33 | 2025 | 557 | 5.300 |
Why?
|
| Prostatic Neoplasms | 53 | 2025 | 1798 | 4.680 |
Why?
|
| Carcinoma, Renal Cell | 23 | 2025 | 366 | 4.360 |
Why?
|
| Urologic Neoplasms | 10 | 2024 | 78 | 3.620 |
Why?
|
| Adenocarcinoma | 24 | 2025 | 1192 | 3.610 |
Why?
|
| Biomarkers, Tumor | 38 | 2025 | 1670 | 3.580 |
Why?
|
| Urinary Bladder | 14 | 2025 | 263 | 3.570 |
Why?
|
| Neoplasm Staging | 32 | 2025 | 2042 | 3.050 |
Why?
|
| Urothelium | 16 | 2025 | 69 | 2.820 |
Why?
|
| Neoplasm Grading | 34 | 2025 | 404 | 2.660 |
Why?
|
| Carcinoma | 15 | 2020 | 444 | 2.340 |
Why?
|
| Adenoma, Oxyphilic | 6 | 2025 | 38 | 2.290 |
Why?
|
| Pathologists | 11 | 2025 | 40 | 1.930 |
Why?
|
| Carcinoma in Situ | 5 | 2025 | 53 | 1.860 |
Why?
|
| Prostate | 18 | 2025 | 423 | 1.670 |
Why?
|
| Pathology, Clinical | 7 | 2025 | 39 | 1.570 |
Why?
|
| Diverticulum | 4 | 2025 | 45 | 1.530 |
Why?
|
| Immunohistochemistry | 28 | 2024 | 1827 | 1.440 |
Why?
|
| Humans | 160 | 2025 | 95799 | 1.330 |
Why?
|
| Urology | 6 | 2025 | 133 | 1.250 |
Why?
|
| Cystadenoma | 3 | 2021 | 18 | 1.230 |
Why?
|
| Carcinoma, Papillary | 7 | 2025 | 161 | 1.140 |
Why?
|
| Male | 100 | 2025 | 45685 | 1.100 |
Why?
|
| Testicular Neoplasms | 4 | 2025 | 122 | 1.080 |
Why?
|
| Diagnosis, Differential | 18 | 2025 | 1613 | 1.060 |
Why?
|
| Neoplasm Invasiveness | 15 | 2025 | 579 | 1.060 |
Why?
|
| Oxyphil Cells | 1 | 2025 | 1 | 0.920 |
Why?
|
| World Health Organization | 4 | 2024 | 122 | 0.910 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2023 | 1087 | 0.870 |
Why?
|
| Precancerous Conditions | 2 | 2025 | 206 | 0.870 |
Why?
|
| Prostatectomy | 13 | 2022 | 480 | 0.860 |
Why?
|
| Urogenital Neoplasms | 1 | 2024 | 25 | 0.830 |
Why?
|
| Rare Diseases | 1 | 2024 | 71 | 0.820 |
Why?
|
| Lymphatic Metastasis | 6 | 2020 | 506 | 0.820 |
Why?
|
| Prognosis | 24 | 2022 | 3990 | 0.790 |
Why?
|
| Neoplasms, Complex and Mixed | 2 | 2014 | 9 | 0.780 |
Why?
|
| Carcinoma, Ductal | 6 | 2020 | 19 | 0.740 |
Why?
|
| Seminal Vesicles | 2 | 2021 | 39 | 0.710 |
Why?
|
| Predictive Value of Tests | 18 | 2025 | 1805 | 0.700 |
Why?
|
| Aged | 46 | 2024 | 20848 | 0.690 |
Why?
|
| Wolffian Ducts | 1 | 2021 | 8 | 0.690 |
Why?
|
| Urethral Neoplasms | 1 | 2021 | 10 | 0.690 |
Why?
|
| Disease Management | 2 | 2020 | 360 | 0.680 |
Why?
|
| Meningioma | 1 | 2021 | 68 | 0.680 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 73 | 0.680 |
Why?
|
| Muscle Proteins | 3 | 2011 | 134 | 0.660 |
Why?
|
| Cytoskeletal Proteins | 3 | 2011 | 227 | 0.650 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 1463 | 0.620 |
Why?
|
| Neoplasm Proteins | 5 | 2020 | 547 | 0.590 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2018 | 17 | 0.570 |
Why?
|
| Antibodies | 3 | 2012 | 356 | 0.560 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2025 | 57 | 0.550 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 171 | 0.550 |
Why?
|
| Middle Aged | 49 | 2024 | 28206 | 0.540 |
Why?
|
| Biopsy | 15 | 2020 | 1208 | 0.530 |
Why?
|
| Models, Statistical | 2 | 2020 | 594 | 0.520 |
Why?
|
| Hemangiosarcoma | 2 | 2014 | 17 | 0.520 |
Why?
|
| Muscle, Smooth | 2 | 2009 | 358 | 0.510 |
Why?
|
| Cystadenocarcinoma | 1 | 2016 | 12 | 0.500 |
Why?
|
| Prostate-Specific Antigen | 9 | 2023 | 346 | 0.490 |
Why?
|
| Aged, 80 and over | 20 | 2024 | 7215 | 0.490 |
Why?
|
| Biopsy, Needle | 5 | 2025 | 231 | 0.470 |
Why?
|
| Observer Variation | 8 | 2025 | 626 | 0.460 |
Why?
|
| Reproducibility of Results | 10 | 2025 | 2882 | 0.440 |
Why?
|
| Choriocarcinoma, Non-gestational | 1 | 2014 | 1 | 0.420 |
Why?
|
| Mucous Membrane | 3 | 2011 | 85 | 0.420 |
Why?
|
| Female | 42 | 2024 | 49869 | 0.420 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2003 | 114 | 0.410 |
Why?
|
| Cell Nucleus | 5 | 2010 | 618 | 0.370 |
Why?
|
| Consensus | 6 | 2025 | 370 | 0.370 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2018 | 365 | 0.370 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 40 | 0.360 |
Why?
|
| Rete Testis | 1 | 2011 | 1 | 0.350 |
Why?
|
| Carcinoma, Embryonal | 1 | 2011 | 2 | 0.350 |
Why?
|
| Terminology as Topic | 5 | 2025 | 227 | 0.350 |
Why?
|
| Leydig Cells | 1 | 2011 | 11 | 0.340 |
Why?
|
| Epididymitis | 1 | 2011 | 5 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2025 | 647 | 0.340 |
Why?
|
| Pluripotent Stem Cells | 1 | 2011 | 38 | 0.340 |
Why?
|
| Ureteral Neoplasms | 3 | 2017 | 13 | 0.330 |
Why?
|
| Adult | 31 | 2024 | 28578 | 0.330 |
Why?
|
| Disease Progression | 5 | 2018 | 1559 | 0.330 |
Why?
|
| Genital Neoplasms, Male | 2 | 2021 | 11 | 0.320 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2009 | 50 | 0.320 |
Why?
|
| Lymph Nodes | 3 | 2016 | 554 | 0.320 |
Why?
|
| Kidney Pelvis | 3 | 2025 | 52 | 0.310 |
Why?
|
| Homeodomain Proteins | 5 | 2024 | 563 | 0.300 |
Why?
|
| Orchiectomy | 2 | 2024 | 63 | 0.300 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2008 | 5 | 0.290 |
Why?
|
| Risk Assessment | 5 | 2020 | 2480 | 0.280 |
Why?
|
| Cysts | 2 | 2014 | 104 | 0.280 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2022 | 23 | 0.280 |
Why?
|
| Specialization | 2 | 2020 | 68 | 0.270 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 117 | 0.270 |
Why?
|
| Cystectomy | 3 | 2020 | 114 | 0.260 |
Why?
|
| Carcinoma, Acinar Cell | 2 | 2017 | 12 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 102 | 0.250 |
Why?
|
| Kidney Tubules, Collecting | 2 | 2018 | 25 | 0.250 |
Why?
|
| Hyperplasia | 2 | 2022 | 149 | 0.250 |
Why?
|
| Mexico | 2 | 2018 | 74 | 0.240 |
Why?
|
| Kidney Medulla | 2 | 2018 | 79 | 0.240 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 16 | 0.240 |
Why?
|
| Stromal Cells | 2 | 2003 | 152 | 0.230 |
Why?
|
| Cell Differentiation | 6 | 2016 | 1662 | 0.230 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 353 | 0.230 |
Why?
|
| Giant Cells | 1 | 2005 | 19 | 0.230 |
Why?
|
| Statistics as Topic | 1 | 2006 | 236 | 0.230 |
Why?
|
| Retroperitoneal Space | 1 | 2005 | 42 | 0.230 |
Why?
|
| Osteoclasts | 1 | 2005 | 38 | 0.230 |
Why?
|
| Rhabdomyosarcoma | 1 | 2005 | 43 | 0.220 |
Why?
|
| Kidney | 3 | 2022 | 1135 | 0.220 |
Why?
|
| Ploidies | 3 | 2018 | 41 | 0.220 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2025 | 108 | 0.220 |
Why?
|
| Carcinoma, Giant Cell | 1 | 2024 | 2 | 0.220 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2024 | 10 | 0.220 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 1079 | 0.210 |
Why?
|
| Antigens, Neoplasm | 3 | 2020 | 357 | 0.210 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2005 | 125 | 0.210 |
Why?
|
| Sperm Retrieval | 1 | 2024 | 3 | 0.210 |
Why?
|
| Nephrectomy | 2 | 2025 | 297 | 0.210 |
Why?
|
| Transcription Factors | 6 | 2024 | 1730 | 0.210 |
Why?
|
| Receptors, Androgen | 2 | 2016 | 120 | 0.210 |
Why?
|
| Graves Disease | 1 | 2004 | 36 | 0.210 |
Why?
|
| Urinary Tract | 1 | 2024 | 33 | 0.210 |
Why?
|
| Fertility Preservation | 1 | 2024 | 21 | 0.200 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 16 | 0.200 |
Why?
|
| Urinary Bladder Diseases | 2 | 2015 | 42 | 0.200 |
Why?
|
| Adenoma | 1 | 2005 | 260 | 0.200 |
Why?
|
| Cerebellopontine Angle | 1 | 2003 | 10 | 0.200 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2002 | 2 | 0.190 |
Why?
|
| Cytogenetic Analysis | 4 | 2007 | 72 | 0.190 |
Why?
|
| Cerebellar Neoplasms | 1 | 2003 | 45 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 111 | 0.190 |
Why?
|
| Quadriplegia | 1 | 2002 | 33 | 0.190 |
Why?
|
| Hepacivirus | 1 | 2003 | 137 | 0.190 |
Why?
|
| Tissue Array Analysis | 5 | 2018 | 132 | 0.190 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2002 | 39 | 0.190 |
Why?
|
| Patient Care Team | 1 | 2025 | 307 | 0.180 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2002 | 9 | 0.180 |
Why?
|
| Sensitivity and Specificity | 6 | 2021 | 2039 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 517 | 0.180 |
Why?
|
| Time Factors | 3 | 2018 | 5561 | 0.180 |
Why?
|
| Lymph Node Excision | 2 | 2016 | 234 | 0.180 |
Why?
|
| Public Health | 1 | 2023 | 155 | 0.180 |
Why?
|
| Neurofibromin 2 | 1 | 2021 | 31 | 0.180 |
Why?
|
| Ki-67 Antigen | 2 | 2020 | 67 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2022 | 111 | 0.180 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 60 | 0.180 |
Why?
|
| Liver Cirrhosis | 1 | 2003 | 276 | 0.180 |
Why?
|
| Pleural Neoplasms | 1 | 2003 | 204 | 0.170 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2002 | 80 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2003 | 184 | 0.170 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 345 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 296 | 0.170 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 250 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 1346 | 0.170 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 2 | 2018 | 20 | 0.160 |
Why?
|
| Kallikreins | 1 | 2020 | 46 | 0.160 |
Why?
|
| Trans-Activators | 1 | 2003 | 446 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 449 | 0.160 |
Why?
|
| Incidental Findings | 2 | 2019 | 99 | 0.160 |
Why?
|
| Muscles | 1 | 2020 | 192 | 0.160 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2020 | 15 | 0.160 |
Why?
|
| Necrosis | 1 | 2020 | 210 | 0.160 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2009 | 78 | 0.150 |
Why?
|
| Databases, Factual | 3 | 2020 | 1010 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 220 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2024 | 9167 | 0.150 |
Why?
|
| Health Resources | 1 | 2020 | 82 | 0.150 |
Why?
|
| Urachus | 1 | 2019 | 2 | 0.150 |
Why?
|
| Urologic Surgical Procedures | 1 | 2021 | 152 | 0.150 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 298 | 0.150 |
Why?
|
| Cell Death | 1 | 2020 | 264 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2024 | 703 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 443 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 398 | 0.150 |
Why?
|
| Databases, Genetic | 1 | 2020 | 284 | 0.150 |
Why?
|
| Mutation | 6 | 2024 | 4374 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 307 | 0.150 |
Why?
|
| beta Catenin | 2 | 2017 | 266 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1267 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2020 | 1753 | 0.140 |
Why?
|
| Retrospective Studies | 12 | 2021 | 10273 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 540 | 0.140 |
Why?
|
| Phenylthiohydantoin | 2 | 2016 | 48 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2017 | 101 | 0.140 |
Why?
|
| United States | 7 | 2021 | 7764 | 0.140 |
Why?
|
| Fumarate Hydratase | 1 | 2018 | 8 | 0.140 |
Why?
|
| Gene Expression | 2 | 2020 | 1319 | 0.140 |
Why?
|
| Phenotype | 3 | 2020 | 2575 | 0.140 |
Why?
|
| Fatal Outcome | 4 | 2009 | 303 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 2 | 2001 | 725 | 0.130 |
Why?
|
| Acinar Cells | 1 | 2017 | 8 | 0.130 |
Why?
|
| Uroplakin III | 2 | 2014 | 4 | 0.130 |
Why?
|
| Liver | 1 | 2002 | 1231 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 149 | 0.130 |
Why?
|
| Mullerian Ducts | 1 | 2016 | 20 | 0.130 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 72 | 0.120 |
Why?
|
| GATA3 Transcription Factor | 2 | 2013 | 52 | 0.120 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2016 | 9 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 484 | 0.120 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 2859 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 73 | 0.120 |
Why?
|
| Urologic Diseases | 1 | 2017 | 42 | 0.120 |
Why?
|
| Incidence | 5 | 2017 | 1714 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2002 | 790 | 0.120 |
Why?
|
| Ureter | 1 | 2017 | 95 | 0.120 |
Why?
|
| Organogenesis | 1 | 2016 | 51 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 136 | 0.120 |
Why?
|
| Mesoderm | 1 | 2016 | 122 | 0.120 |
Why?
|
| Young Adult | 6 | 2018 | 7026 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2020 | 454 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2000 | 426 | 0.120 |
Why?
|
| Signal Transduction | 6 | 2018 | 3581 | 0.120 |
Why?
|
| Logistic Models | 4 | 2023 | 1267 | 0.120 |
Why?
|
| Karyotyping | 2 | 2007 | 224 | 0.120 |
Why?
|
| Survival Rate | 4 | 2015 | 1971 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 766 | 0.110 |
Why?
|
| Xanthomatosis | 1 | 2015 | 5 | 0.110 |
Why?
|
| Neoplasms | 2 | 2021 | 3242 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 644 | 0.110 |
Why?
|
| Algorithms | 1 | 2023 | 2015 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2016 | 1540 | 0.110 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 2385 | 0.110 |
Why?
|
| Benzamides | 4 | 2016 | 248 | 0.110 |
Why?
|
| Uroplakin II | 1 | 2014 | 1 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2015 | 218 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 2474 | 0.100 |
Why?
|
| Gene Expression Profiling | 5 | 2016 | 1535 | 0.100 |
Why?
|
| Urologists | 2 | 2025 | 34 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1739 | 0.100 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2012 | 19 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2014 | 322 | 0.090 |
Why?
|
| Pathology, Molecular | 1 | 2012 | 34 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 2012 | 44 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 96 | 0.090 |
Why?
|
| Hyaluronan Receptors | 2 | 2012 | 40 | 0.090 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 53 | 0.090 |
Why?
|
| Sarcoma | 2 | 2005 | 224 | 0.090 |
Why?
|
| Thymus Gland | 1 | 2013 | 206 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 556 | 0.090 |
Why?
|
| Risk Factors | 3 | 2018 | 5961 | 0.090 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 7 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 1310 | 0.090 |
Why?
|
| Adrenogenital Syndrome | 1 | 2011 | 1 | 0.090 |
Why?
|
| 17-Ketosteroids | 1 | 2011 | 13 | 0.090 |
Why?
|
| Tropism | 1 | 2011 | 4 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2011 | 22 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 655 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2025 | 644 | 0.080 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2024 | 23 | 0.080 |
Why?
|
| Piperazines | 2 | 2003 | 296 | 0.080 |
Why?
|
| Papilloma | 1 | 2011 | 23 | 0.080 |
Why?
|
| Cell Shape | 1 | 2011 | 50 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2011 | 86 | 0.080 |
Why?
|
| Hemangioma, Capillary | 1 | 2010 | 8 | 0.080 |
Why?
|
| Vascular Neoplasms | 1 | 2010 | 21 | 0.080 |
Why?
|
| Image Cytometry | 2 | 2007 | 12 | 0.080 |
Why?
|
| Pyrimidines | 2 | 2003 | 386 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2013 | 385 | 0.080 |
Why?
|
| DNA, Neoplasm | 4 | 2018 | 272 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2022 | 2777 | 0.080 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 50 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 350 | 0.080 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2009 | 3 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 432 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2013 | 447 | 0.080 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2009 | 1 | 0.080 |
Why?
|
| Thrombopoiesis | 1 | 2009 | 6 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 200 | 0.080 |
Why?
|
| Adolescent | 4 | 2018 | 9873 | 0.070 |
Why?
|
| Interdisciplinary Communication | 2 | 2025 | 135 | 0.070 |
Why?
|
| PAX2 Transcription Factor | 1 | 2009 | 6 | 0.070 |
Why?
|
| Erythroid Precursor Cells | 1 | 2009 | 33 | 0.070 |
Why?
|
| Pelvis | 1 | 2009 | 103 | 0.070 |
Why?
|
| Carbonic Anhydrases | 1 | 2009 | 15 | 0.070 |
Why?
|
| Histiocytosis, Sinus | 1 | 2008 | 17 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2009 | 128 | 0.070 |
Why?
|
| Anaplasia | 1 | 2008 | 5 | 0.070 |
Why?
|
| Desmin | 1 | 2008 | 10 | 0.070 |
Why?
|
| Myogenin | 1 | 2008 | 5 | 0.070 |
Why?
|
| Synaptophysin | 1 | 2008 | 11 | 0.070 |
Why?
|
| MyoD Protein | 1 | 2008 | 16 | 0.070 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 59 | 0.070 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2009 | 57 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 152 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 591 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 187 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2011 | 356 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1425 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2007 | 61 | 0.070 |
Why?
|
| Transcriptome | 1 | 2013 | 770 | 0.070 |
Why?
|
| Societies, Scientific | 1 | 2007 | 43 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 587 | 0.060 |
Why?
|
| Robotics | 1 | 2009 | 273 | 0.060 |
Why?
|
| Cadherins | 1 | 2007 | 179 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 555 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 223 | 0.060 |
Why?
|
| Imatinib Mesylate | 2 | 2003 | 127 | 0.060 |
Why?
|
| Wilms Tumor | 1 | 2005 | 37 | 0.060 |
Why?
|
| Radiotherapy | 2 | 2018 | 325 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 3639 | 0.060 |
Why?
|
| Cell Division | 2 | 2004 | 701 | 0.060 |
Why?
|
| Pathology | 1 | 2025 | 36 | 0.060 |
Why?
|
| Sphingosine | 1 | 2005 | 74 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2017 | 3106 | 0.060 |
Why?
|
| Nephrons | 1 | 2004 | 17 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1096 | 0.050 |
Why?
|
| Chicago | 2 | 2021 | 1505 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 86 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2024 | 1422 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2005 | 265 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 1194 | 0.050 |
Why?
|
| Biomarkers | 1 | 2011 | 1931 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2024 | 70 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2005 | 150 | 0.050 |
Why?
|
| Seminoma | 1 | 2024 | 15 | 0.050 |
Why?
|
| Nitriles | 2 | 2016 | 157 | 0.050 |
Why?
|
| Thyrotoxicosis | 1 | 2004 | 18 | 0.050 |
Why?
|
| Telomerase | 1 | 2024 | 68 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2024 | 109 | 0.050 |
Why?
|
| Herpesvirus 8, Human | 1 | 2003 | 11 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2024 | 71 | 0.050 |
Why?
|
| HIV Seronegativity | 1 | 2003 | 14 | 0.050 |
Why?
|
| Carcinoma, Lobular | 1 | 2004 | 85 | 0.050 |
Why?
|
| Herpesviridae Infections | 1 | 2003 | 46 | 0.050 |
Why?
|
| ROC Curve | 2 | 2021 | 797 | 0.050 |
Why?
|
| Tyrphostins | 1 | 2003 | 7 | 0.050 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 126 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2003 | 226 | 0.050 |
Why?
|
| Thyroidectomy | 1 | 2004 | 173 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 4664 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2003 | 89 | 0.050 |
Why?
|
| HIV-1 | 1 | 2003 | 182 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 279 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 354 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2018 | 477 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2007 | 297 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 137 | 0.050 |
Why?
|
| Carcinosarcoma | 1 | 2002 | 29 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 528 | 0.050 |
Why?
|
| Perception | 1 | 2023 | 185 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 207 | 0.040 |
Why?
|
| Laparotomy | 1 | 2002 | 63 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2022 | 51 | 0.040 |
Why?
|
| Mice | 5 | 2016 | 12537 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 29 | 0.040 |
Why?
|
| Glycolysis | 1 | 2022 | 191 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 3155 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2003 | 1156 | 0.040 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2000 | 3 | 0.040 |
Why?
|
| Apoptosis | 2 | 2005 | 1756 | 0.040 |
Why?
|
| Bile | 1 | 2000 | 61 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2013 | 830 | 0.040 |
Why?
|
| Carcinoma, Large Cell | 1 | 2000 | 39 | 0.040 |
Why?
|
| Patient Care | 1 | 2021 | 101 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 478 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 488 | 0.040 |
Why?
|
| Animals | 6 | 2016 | 28889 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 295 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2013 | 705 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 134 | 0.040 |
Why?
|
| Urinary Diversion | 1 | 2018 | 44 | 0.030 |
Why?
|
| Pregnancy | 1 | 2005 | 3237 | 0.030 |
Why?
|
| Brazil | 1 | 2018 | 82 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 124 | 0.030 |
Why?
|
| Mitochondria | 1 | 2022 | 621 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 214 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 349 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 2 | 2009 | 245 | 0.030 |
Why?
|
| Human Embryonic Stem Cells | 1 | 2016 | 5 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 372 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2017 | 68 | 0.030 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2016 | 20 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 547 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1766 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 64 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2495 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2016 | 76 | 0.030 |
Why?
|
| Epithelium | 1 | 2016 | 322 | 0.030 |
Why?
|
| Urethra | 1 | 2016 | 115 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 235 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2016 | 238 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 393 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 701 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 324 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 883 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 157 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 91 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 188 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 910 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1560 | 0.030 |
Why?
|
| HIV Infections | 1 | 2003 | 974 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 306 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2015 | 161 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 322 | 0.030 |
Why?
|
| Infant | 2 | 2011 | 3360 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2013 | 48 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2012 | 7 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2013 | 82 | 0.020 |
Why?
|
| Keratin-14 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Desmoglein 3 | 1 | 2012 | 6 | 0.020 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Child | 2 | 2018 | 7618 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 87 | 0.020 |
Why?
|
| Decision Trees | 1 | 2012 | 63 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 98 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2536 | 0.020 |
Why?
|
| Autoantigens | 1 | 2013 | 139 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 120 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 81 | 0.020 |
Why?
|
| Illinois | 1 | 2013 | 530 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 180 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 144 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 197 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 301 | 0.020 |
Why?
|
| Mucins | 1 | 2009 | 40 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 465 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1809 | 0.020 |
Why?
|
| Thrombocytosis | 1 | 2009 | 8 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3904 | 0.020 |
Why?
|
| Granulocytes | 1 | 2009 | 37 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2009 | 38 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2009 | 11 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3491 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1645 | 0.020 |
Why?
|
| Cell Size | 1 | 2009 | 71 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 562 | 0.020 |
Why?
|
| Leukopenia | 1 | 2009 | 65 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1211 | 0.020 |
Why?
|
| Jaundice, Obstructive | 1 | 2008 | 11 | 0.020 |
Why?
|
| Histiocytes | 1 | 2008 | 23 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2008 | 31 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 138 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 189 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2008 | 53 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 684 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2009 | 154 | 0.020 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2008 | 34 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2009 | 252 | 0.020 |
Why?
|
| Anemia | 1 | 2009 | 136 | 0.020 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2007 | 8 | 0.020 |
Why?
|
| Carcinoma, Medullary | 1 | 2007 | 9 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 70 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2007 | 66 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 599 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2009 | 415 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 816 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2007 | 61 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 897 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2007 | 88 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 480 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2089 | 0.020 |
Why?
|
| Photometry | 1 | 2006 | 13 | 0.020 |
Why?
|
| Macrophages | 1 | 2009 | 623 | 0.010 |
Why?
|
| Co-Repressor Proteins | 1 | 2005 | 25 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 69 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 79 | 0.010 |
Why?
|
| Clavicle | 1 | 2004 | 13 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 175 | 0.010 |
Why?
|
| Frozen Sections | 1 | 2005 | 50 | 0.010 |
Why?
|
| Mitotic Index | 1 | 2004 | 22 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 209 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2005 | 127 | 0.010 |
Why?
|
| Axilla | 1 | 2005 | 110 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2005 | 278 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 760 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 2161 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2004 | 163 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 796 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2005 | 526 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 307 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 396 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 1029 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2002 | 80 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 316 | 0.010 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2001 | 5 | 0.010 |
Why?
|
| Lymphangioma | 1 | 2001 | 15 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 681 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 3970 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2001 | 68 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 750 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 1319 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 2592 | 0.010 |
Why?
|